List of Excipients in Branded Drug SYMFI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Viatris Specialty LLC	SYMFI	efavirenz, lamivudine and tenofovir disoproxil fumarate	49502-475	CELLULOSE, MICROCRYSTALLINE
Viatris Specialty LLC	SYMFI	efavirenz, lamivudine and tenofovir disoproxil fumarate	49502-475	CROSCARMELLOSE SODIUM
Viatris Specialty LLC	SYMFI	efavirenz, lamivudine and tenofovir disoproxil fumarate	49502-475	HYDROXYPROPYL CELLULOSE
Viatris Specialty LLC	SYMFI	efavirenz, lamivudine and tenofovir disoproxil fumarate	49502-475	LACTOSE MONOHYDRATE
Viatris Specialty LLC	SYMFI	efavirenz, lamivudine and tenofovir disoproxil fumarate	49502-475	MAGNESIUM STEARATE
Viatris Specialty LLC	SYMFI	efavirenz, lamivudine and tenofovir disoproxil fumarate	49502-475	POLYETHYLENE GLYCOL

SYMFI Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

SYMFI is a once-daily fixed-dose HIV tablet containing efavirenz 600 mg, emtricitabine 200 mg, and tenofovir disoproxil fumarate 300 mg. SYMFI LO contains lower-dose efavirenz, 400 mg, with the same emtricitabine and tenofovir disoproxil fumarate doses. The commercial opportunity is primarily in cost reduction, supply-chain resilience, regional substitution, and improved oral performance rather than new-molecule exclusivity.

The strongest excipient strategy combines direct-compression manufacturability with control of efavirenz dissolution, tablet size, moisture exposure, and coating robustness. Novel excipient claims may be difficult to defend because the active ingredients and basic fixed-dose combination are established. Commercial protection is more likely to come from manufacturing know-how, formulation patents, regulatory filings, trademarks, and reliable supply.

What is SYMFI and which excipients does it contain?

SYMFI is an FDA-approved fixed-dose combination for the treatment of HIV-1 infection in adults and pediatric patients meeting the labeled weight requirements. SYMFI LO uses a reduced efavirenz dose and has a different clinical positioning within the same product family.[1,2]

SYMFI active ingredients and dosage strengths

Product	Efavirenz	Emtricitabine	Tenofovir disoproxil fumarate	Administration
SYMFI	600 mg	200 mg	300 mg	Once daily
SYMFI LO	400 mg	200 mg	300 mg	Once daily

The tablets are large, high-drug-load solid oral products. Efavirenz has low aqueous solubility and can create dissolution and content-uniformity challenges. Emtricitabine is comparatively water-soluble. Tenofovir disoproxil fumarate contributes substantial mass and has known sensitivity to hydrolytic degradation, making moisture control important during granulation, compression, coating, and packaging.[1-3]

Public U.S. labeling identifies conventional pharmaceutical excipients used for tablet manufacture and film coating. Depending on the product and market presentation, these include cellulose-based fillers and binders, croscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide, magnesium stearate, hypromellose, polyethylene glycol, titanium dioxide, and colorants.[1,2] The exact quantitative composition is not fully disclosed in the commercial label.

What excipient functions are most important in SYMFI?

The formulation must manage five technical requirements: high drug loading, efavirenz dissolution, uniform distribution of three active ingredients, tablet mechanical strength, and protection from moisture.

Diluent and compression system

Microcrystalline cellulose is a logical primary diluent because it supports direct compression and contributes plastic deformation. The high active load limits the amount of conventional filler available, so the formulation must achieve adequate tablet hardness without excessive tablet size.

Mannitol, lactose, dibasic calcium phosphate, or spray-dried composite excipients could be evaluated as alternatives. Each option creates different development tradeoffs:

Excipient platform	Potential benefit	Principal risk
Microcrystalline cellulose	Strong compaction and established regulatory status	Can increase tablet bulk and affect disintegration
Mannitol	Low hygroscopicity and clean mouthfeel	May require binder optimization
Lactose	Low cost and broad availability	Maillard compatibility concerns with some amine-containing materials
Dibasic calcium phosphate	High density and low moisture uptake	Brittle compaction and potential dissolution impact
Coprocessed excipient	Improved flow, compactability, and process consistency	Higher cost and formulation-specific supplier dependence

For a generic or regional product, a coprocessed cellulose-silica system could reduce blend segregation and improve tablet weight control. The commercial value would be greatest where existing equipment has limited feeder precision or where the manufacturer wants to avoid wet granulation.

Binder and granulation system

Hydroxypropyl cellulose or povidone can improve granule strength and reduce friability. Excess binder can slow disintegration and efavirenz dissolution. The target is a binder level that provides robust tablets without creating a hydrophobic or overly dense matrix.

Wet granulation may improve content uniformity when the three active ingredients have different particle-size distributions and densities. Direct compression is commercially attractive because it reduces processing steps, but it places greater demands on particle engineering and blend segregation control.

A high-value development route is to use dry granulation or roller compaction for efavirenz and then blend with the other active ingredients under controlled shear. This approach can reduce water exposure to tenofovir disoproxil fumarate while preserving throughput.

Disintegrant strategy

Croscarmellose sodium is suitable for rapid tablet breakup, particularly in a high-load tablet. Sodium starch glycolate and crospovidone are alternatives.

Crospovidone may be attractive where rapid capillary action and low gelling behavior are required. Croscarmellose sodium can provide strong swelling but may require careful control of compression force. Sodium starch glycolate can be cost-effective, although overuse may produce excessive swelling or affect tablet robustness.

The key performance metric is not simply disintegration time. The formulation must demonstrate consistent efavirenz dissolution across dissolution media and manufacturing scale. A formulation that disintegrates rapidly but releases efavirenz slowly may fail comparative performance testing.

Surfactant and wetting system

Sodium lauryl sulfate can improve wetting of efavirenz and support dissolution. Its level must be controlled because excessive surfactant may affect tablet mechanical properties, gastrointestinal tolerability, and dissolution profiles.

Poloxamers, sodium docusate, or certain wetting aids could be evaluated as alternatives. A surfactant substitution may provide a formulation patent opportunity if it produces a measurable dissolution advantage without changing the active pharmaceutical ingredients.

Lubricant and glidant system

Magnesium stearate is widely used but can create dissolution delays when over-lubrication produces hydrophobic particle surfaces. The formulation should use controlled blending time and a validated endpoint.

Colloidal silicon dioxide can improve powder flow and reduce feeder variability. It may also reduce the impact of poor particle morphology. A silica-based glidant should be assessed for segregation because very low-density particles can redistribute during transfer.

Film coating and moisture protection

The coating should protect the tablet, support product identification, and limit moisture ingress without materially increasing tablet dimensions. Hypromellose-based coatings with polyethylene glycol plasticizer are conventional options.

For tenofovir disoproxil fumarate products, moisture control has commercial importance. A low-moisture coating, high-barrier blister, or desiccant-containing bottle can reduce degradation risk. Packaging can be a more practical protection strategy than a complex excipient system.

What formulation patents could protect SYMFI products?

The strongest formulation patent opportunities would involve measurable technical effects rather than routine excipient substitution.

Potential claim areas include:

1. A low-moisture tablet containing efavirenz, emtricitabine, and tenofovir disoproxil fumarate with defined water activity.
2. A specific particle-size or micronization range for efavirenz.
3. A surfactant-dispersant system that improves efavirenz dissolution.
4. A dry-granulated composition with defined granule-size distribution.
5. A tablet with reduced mass or thickness while maintaining dissolution and hardness.
6. A packaging system that limits degradation of tenofovir disoproxil fumarate.
7. A formulation with improved storage stability under tropical or high-humidity conditions.
8. A pediatric or swallowability-oriented dosage form, where permitted by the clinical and regulatory strategy.

Routine use of microcrystalline cellulose, croscarmellose sodium, magnesium stearate, or hypromellose alone is unlikely to provide strong patent differentiation. Patent value would depend on demonstrated performance, narrow composition ranges, process controls, and comparative stability or dissolution data.

When does SYMFI lose exclusivity?

SYMFI was approved by FDA in 2017, and SYMFI LO was approved in 2018.[1,2] The products contain previously known active ingredients, so the primary U.S. regulatory protection was not expected to resemble a new chemical entity five-year exclusivity period.

Milestone	SYMFI	SYMFI LO
FDA approval	2017	2018
Likely three-year new clinical investigation exclusivity window	Expired around 2020	Expired around 2021
Active ingredients	Established	Established
Generic pathway	ANDA or other applicable abbreviated pathway	ANDA or other applicable abbreviated pathway
Biosimilar pathway	Not applicable	Not applicable

The precise generic-entry analysis depends on current Orange Book listings, approved patents, pediatric extensions, litigation, and any later supplements. SYMFI is a small-molecule tablet, not a biologic, so biosimilar litigation is not relevant. The relevant competitors are generic fixed-dose combinations, separate-component regimens, and alternative branded HIV regimens.

What is the Orange Book status of SYMFI?

SYMFI and SYMFI LO are FDA-approved small-molecule drug products and are evaluated through the FDA’s Orange Book framework. Orange Book status can change through patent listing updates, product discontinuation notices, supplements, and changes in the reference-listed drug record.[4]

A commercial diligence review should distinguish among:

• patents listed for the reference product;
• patents that remain unexpired;
• patents eligible for Paragraph IV certification;
• regulatory exclusivity that has expired;
• patents covering the active ingredients generally;
• patents covering only a particular formulation, use, or manufacturing method.

The existence of an Orange Book patent does not establish that a generic product infringes it. A generic applicant may file a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed. Conversely, the absence of a meaningful current Orange Book barrier does not eliminate manufacturing, supply, regulatory, or market-access risk.

Which companies are challenging SYMFI or competing with it?

The competitive field includes generic manufacturers with HIV fixed-dose combination capabilities, suppliers of the individual components, and branded companies selling newer integrase inhibitor-based regimens.

Generic competition

The most credible generic entrants are companies with:

• established antiretroviral manufacturing;
• access to efavirenz, emtricitabine, and tenofovir disoproxil fumarate API;
• FDA, EMA, WHO, or national regulatory experience;
• stability data from hot and humid climates;
• government tender infrastructure;
• capability to manage bioequivalence for a high-load tablet.

A generic company may choose to copy the commercial dosage form or develop a smaller tablet, a different coating, or a more robust packaging configuration. The latter options can create product differentiation but may increase bioequivalence and manufacturing complexity.

Branded regimen competition

SYMFI competes with newer single-tablet and fixed-dose HIV regimens, particularly products based on integrase strand transfer inhibitors. Treatment guidelines have shifted toward integrase inhibitor-based therapy in many settings because of efficacy, tolerability, resistance, and drug-interaction considerations.[5]

SYMFI retains commercial relevance where low acquisition cost, established supply, and once-daily dosing are decisive. The product is less advantaged in markets where clinicians prioritize newer first-line regimens or where efavirenz-related central nervous system and drug-interaction concerns reduce use.

What commercial opportunities exist for SYMFI excipients?

The commercial opportunity is strongest in excipient-enabled cost and performance improvements.

Lower-cost global supply

A manufacturer can create value by replacing a single-source excipient with a qualified multi-source system. The replacement should preserve dissolution, tablet hardness, stability, and bioequivalence. Local sourcing may improve government-tender economics and reduce freight exposure.

Tropical stability

Many HIV products are distributed in regions with high humidity and elevated temperature. A formulation using lower-moisture excipients, tighter water-activity controls, and high-barrier packaging could support longer shelf life or reduce stability failures.

This opportunity is particularly relevant for public-health procurement, where a lower-cost bottle with reliable stability may outperform a more expensive formulation with no measurable clinical advantage.

Smaller and more swallowable tablets

SYMFI has a substantial drug load. Reducing tablet volume could improve adherence and patient acceptance. Candidate approaches include:

• high-density diluents;
• roller compaction;
• optimized particle engineering;
• coprocessed excipients;
• lower-volume film coatings;
• improved compression tooling.

A smaller tablet must maintain rapid disintegration, acceptable dissolution, mechanical strength, and stable content uniformity.

Pediatric and differentiated presentations

Pediatric HIV treatment remains a formulation opportunity. A dispersible tablet, sprinkle formulation, or age-appropriate dosage form could address swallowing limitations. The regulatory burden is higher because taste, dose flexibility, stability after dispersion, and pediatric bioequivalence must be addressed.

Efavirenz taste and odor are important development constraints. Taste masking may require polymeric coatings, lipid-based granules, or multiparticulate systems. Any new dosage form would need to preserve dose accuracy and control exposure to caregivers and children.

Excipient supplier partnerships

Excipient companies could pursue value-added offerings rather than commodity supply. Relevant products include:

• direct-compression platforms;
• low-moisture fillers;
• co-processed binders and disintegrants;
• efavirenz wetting systems;
• roller-compaction aids;
• high-barrier coating systems;
• stability packages for tropical climates.

The most defensible commercial position would be a qualified formulation platform supported by comparative dissolution, scale-up, stability, and regulatory documentation.

How strong is the SYMFI formulation patent estate?

The underlying active ingredients are mature, which limits the exclusivity value of broad composition claims. A formulation patent could still be commercially meaningful if it covers a necessary product attribute, such as improved dissolution, stability, reduced tablet size, or a specific manufacturing process.

Patent strength should be assessed against five factors:

Factor	Strong position	Weak position
Claim scope	Defined composition and process with measurable effect	Generic list of conventional excipients
Technical effect	Improved dissolution, stability, or manufacturability	No comparative advantage
Enablement	Multiple examples and reproducible process	Single narrow example
Freedom to operate	No blocking third-party claims	Overlap with known fixed-dose products
Market relevance	Feature required by procurement or regulation	Feature with no price or access benefit

Manufacturing know-how may be more valuable than a broad excipient patent. Blend order, lubrication time, granulation endpoint, moisture limits, and packaging configuration can materially affect product quality while remaining difficult for competitors to replicate.

What generic launch scenarios exist for SYMFI?

Three launch scenarios are commercially plausible.

Price-led substitution

A generic manufacturer launches a conventional tablet using established excipients and competes through lower price. This is the most straightforward route but exposes the company to tender compression and limited brand loyalty.

Quality-differentiated substitution

The entrant uses improved moisture protection, smaller tablet dimensions, or superior dissolution consistency. This approach can support preferred-supplier status, particularly in public-health programs, but requires stronger regulatory and manufacturing evidence.

Regional supply strategy

A company targets markets where SYMFI or similar products are used under government procurement, donor programs, or national HIV treatment protocols. Local registration, WHO prequalification, packaging localization, and reliable supply may matter more than U.S. patent barriers.

What licensing deals are relevant to SYMFI?

Licensing opportunities may involve:

• regional rights to a finished fixed-dose combination;
• API supply agreements;
• technology transfer for direct compression or dry granulation;
• excipient platform licenses;
• contract manufacturing;
• government or donor procurement frameworks.

The key diligence issue is whether the deal covers only the finished product or also includes formulation know-how, analytical methods, stability data, regulatory files, trademarks, and manufacturing rights. For a mature combination, know-how transfer and regulatory support can be more valuable than nominal patent rights.

Key Takeaways

• SYMFI combines efavirenz, emtricitabine, and tenofovir disoproxil fumarate in a once-daily tablet; SYMFI LO reduces the efavirenz dose.
• The principal formulation challenges are efavirenz dissolution, high drug loading, content uniformity, tablet size, and tenofovir disoproxil fumarate stability.
• Microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide, magnesium stearate, and hypromellose are commercially relevant excipient tools.
• The best commercial opportunities are lower-cost supply, tropical stability, smaller tablets, pediatric presentations, and qualified multi-source excipient systems.
• Broad excipient patents are likely to be weak unless supported by a defined technical effect and comparative data.
• SYMFI is a small-molecule product, so biosimilar risk does not apply.
• Generic competition is more likely to be driven by regulatory access, tender economics, manufacturing reliability, and formulation performance than by long-lived molecule patents.
• Newer integrase inhibitor-based regimens create substantial branded competitive pressure in first-line HIV treatment.

FAQs

Can SYMFI be reformulated as a smaller tablet?

Yes. High-density excipients, particle engineering, dry granulation, and optimized compression can reduce tablet volume. The reformulated product must preserve dissolution, content uniformity, stability, and bioequivalence.

Is efavirenz the main excipient-development problem in SYMFI?

Yes. Efavirenz has low aqueous solubility and is the most likely component to drive wetting, particle-size, surfactant, and dissolution optimization.

Are biosimilars relevant to SYMFI?

No. SYMFI contains chemically synthesized small-molecule active ingredients. Competition proceeds through generic and abbreviated drug-approval pathways rather than biosimilar approval.

Could a moisture-protective package be patentable for SYMFI?

Potentially. Patentability would depend on the claimed package, moisture-control parameters, stability benefit, and non-obviousness. A conventional bottle or blister alone is unlikely to provide strong protection.

Is a pediatric SYMFI formulation commercially attractive?

It can be attractive in markets with pediatric HIV treatment demand, but taste masking, dose flexibility, dispersion stability, caregiver handling, and pediatric regulatory requirements increase development cost.

References

1. U.S. Food and Drug Administration. (2017). SYMFI (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) prescribing information.

2. U.S. Food and Drug Administration. (2018). SYMFI LO (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) prescribing information.

3. U.S. Food and Drug Administration. (2023). Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

5. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services.